In summary, this study confirmed that chronic treatment with pioglitazone, a PPARγ agonist, not only ameliorates systematic insulin resistance and decreases plasma TG but also exacerbates hepatic steatosis and liver lesions in obese diabetic KKAy mice. This evidence concerns the gene PPARG and fatty liver disease.